Business
Werewolf Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
– WTX-124 Phase 1/1b clinical trial on track for data readouts and interactions with the FDA in the second half of the year – – First patient dosed in the Phase 1b/2 clinical trial of WTX-330, seeking to build on the clinical activity and tolerability demonstrated in the recently completed WTX-330 first-in-human Phase 1 trial – – Company announces development of its proprietary INDUCER™ T cell engager molecules; development candidate targeted by the end of the second quarter of 2025 – – Updated
About this update from Werewolf Therapeutics, Inc.
[{"type":"image","alt":"Werewolf Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Werewolf Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":158,"url":"https://media.zenfs.com/en/globenewswire.com/3a0b348d8361243b3fb2ff9099161d3c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/C6Y97KmUdGS6XpzuliXDig--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIyMTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/3a0b348d8361243b3fb2ff9099161d3c","width":300,"height":158}},"lazy":false},{"type":"text","content":"– WTX-124 Phase 1/1b clinical trial on track for data readouts and interactions with the FDA in the second half of the year –","length":130,"tagName":"p"},{"type":"text","content":"– First patient dosed in the Phase 1b/2 clinical trial of WTX-330, seeking to build on the clinical activity and tolerability demonstrated in the recently completed WTX-330 first-in-human Phase 1 trial –","length":203,"tagName":"p"},{"type":"text","content":"– Company announces development of its proprietary INDUCER™ T cell engager molecules; development candidate targeted by the end of the second quarter of 2025 –","length":164,"tagName":"p"},{"type":"text","content":"– Updated cash guidance provides runway into the fourth quarter of 2026 – ","length":73,"tagName":"p"},{"type":"text","content":"WATERTOWN, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other immune-mediated conditions, today provided a business update and reported financial results for the first quarter ended March 31, 2025.","length":459,"tagName":"p"},{"type":"text","content":"“Werewolf continues to build on our promising data and progress across our clinical-stage programs,” said Daniel J. Hicklin, Ph.D., President and Chief Executive Officer of Werewolf. “We remain on track in our Phase 1/1b clinical trial evaluating WTX-124 to share interim data and meet with the FDA to discuss potential registrational pathways in the second half of this year. Additionally, in recognition of Skin Cancer Awareness month, Werewolf is launching an educational campaign in May to highlight the differe...